28533939|t|Efficacy of peptide receptor radionuclide therapy with (177)Lu-octreotate in metastatic pulmonary neuroendocrine tumors: a dual-centre analysis
28533939|a|There is lack of data on the specific benefit of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors (NET) of pulmonary origin. This dual- centre study aimed to assess outcome and toxicity of standardized PRRT with (177)Lu-octreotate in a patient population of advanced pulmonary NET of grade 1-2. We retrospectively assessed 22 consecutively patients treated with 4 intended cycles at 3 monthly intervals (mean activity per cycle 7.8±0.68 GBq). In a median follow-up period of 54 months, no significant nephrotoxicity (≥ grade 3) was observed. Reversible hematotoxicity (grade 3) occurred in 3 patients (13.6%). Treatment response consisted of partial response in 6 (27.3%), stable disease in 9 (40.9%), and progressive disease in 7 (31.8%) patients. Median progression-free survival (PFS) and overall survival (OS) was 27 (95% CI, 9-45) and 42 months (95% CI, 25-59), respectively. High hepatic tumor load (> 50%) and high plasma chromogranin A (> 600 ng/mL) were negative baseline predictors for PFS and OS on univariate analysis, CgA remained significant on multivariate analysis (PFS, P=0.011; OS, P=0.026). Disease progression despite PRRT was associated with shorter survival (median OS 15 vs 53 mo, P<0.001). Despite a higher incidence of treatment failure compared to NET of other origins, the observed substantial and sustained disease stabilization (median PFS of 27 mo, disease control rate of > 2/3 of pts) indicates considerable efficacy of (177)Lu-octreotate in pulmonary NET.
28533939	0	8	Efficacy	T080	C1280519
28533939	12	28	peptide receptor	T116,T192	C0206473
28533939	29	49	radionuclide therapy	T061	C0203608
28533939	55	73	(177)Lu-octreotate	T121	C1254351
28533939	77	87	metastatic	T169	C1522484
28533939	88	97	pulmonary	T023	C0024109
28533939	98	119	neuroendocrine tumors	T191	C0206754
28533939	135	143	analysis	T062	C0936012
28533939	193	209	peptide receptor	T116,T192	C0206473
28533939	210	230	radionuclide therapy	T061	C0203608
28533939	232	236	PRRT	T061	C0203608
28533939	241	262	neuroendocrine tumors	T191	C0206754
28533939	264	267	NET	T191	C0206754
28533939	272	281	pulmonary	T023	C0024109
28533939	308	313	study	T062	C2603343
28533939	330	337	outcome	T080	C0085415
28533939	342	350	toxicity	T037	C0600688
28533939	367	371	PRRT	T061	C0203608
28533939	377	395	(177)Lu-octreotate	T121	C1254351
28533939	401	408	patient	T101	C0030705
28533939	432	441	pulmonary	T023	C0024109
28533939	442	445	NET	T191	C0206754
28533939	449	458	grade 1-2	T185	C0441800
28533939	505	513	patients	T101	C0030705
28533939	514	526	treated with	T061	C0332293
28533939	558	567	intervals	T079	C1272706
28533939	620	629	follow-up	T058	C1522577
28533939	643	649	months	T079	C0439231
28533939	666	680	nephrotoxicity	T037	C0599918
28533939	684	691	grade 3	T185	C0441800
28533939	718	732	hematotoxicity	T046	C0920103
28533939	734	741	grade 3	T185	C0441800
28533939	757	765	patients	T101	C0030705
28533939	775	793	Treatment response	T201	C0521982
28533939	838	852	stable disease	T033	C0677946
28533939	871	890	progressive disease	T047	C1335499
28533939	904	912	patients	T101	C0030705
28533939	921	946	progression-free survival	T081	C0242792
28533939	948	951	PFS	T081	C0242792
28533939	957	973	overall survival	T081	C4086681
28533939	975	977	OS	T081	C4086681
28533939	991	993	CI	T081	C0009667
28533939	1008	1014	months	T079	C0439231
28533939	1020	1022	CI	T081	C0009667
28533939	1051	1064	hepatic tumor	T191	C0023903
28533939	1087	1108	plasma chromogranin A	T116,T125,T130	C0055633
28533939	1137	1145	baseline	T081	C1442488
28533939	1146	1156	predictors	T078	C2698872
28533939	1161	1164	PFS	T081	C0242792
28533939	1169	1171	OS	T081	C4086681
28533939	1175	1194	univariate analysis	T062	C0683962
28533939	1196	1199	CgA	T116,T125,T130	C0055633
28533939	1224	1245	multivariate analysis	T081	C0026777
28533939	1247	1250	PFS	T081	C0242792
28533939	1261	1263	OS	T081	C4086681
28533939	1275	1294	Disease progression	T046	C0242656
28533939	1303	1307	PRRT	T061	C0203608
28533939	1336	1344	survival	T052	C0038952
28533939	1353	1355	OS	T081	C4086681
28533939	1396	1405	incidence	T081	C0021149
28533939	1409	1426	treatment failure	T033	C0162643
28533939	1439	1442	NET	T191	C0206754
28533939	1500	1507	disease	T047	C0012634
28533939	1508	1521	stabilization	T061	C1293130
28533939	1530	1533	PFS	T081	C0242792
28533939	1544	1559	disease control	T061	C0920467
28533939	1605	1613	efficacy	T080	C1280519
28533939	1617	1635	(177)Lu-octreotate	T121	C1254351
28533939	1639	1648	pulmonary	T023	C0024109
28533939	1649	1652	NET	T191	C0206754